Fusion polypeptides for metabolic disorders
US12331093B2 · kind B2 · utility
0Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2023 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Jun 5, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. The present disclosure further provides conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.